Mohammed Qayyum, MD
Cardiovascular Disease · San Jose, CANPI 1679666994
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $113,000 of the $132,262 with a category attached, or 85.4%. Preventice Services, LLC accounts for 78.6% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2020 at $39,886 and has fallen 96.7% since, to $1,321 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $298.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Preventice Services, LLC$104K
- Boston Scientific$9K
- Acist Medical Systems, Inc.$3K
- Abbott$3K
- Biotronik Inc.$2K
- Actelion Pharmaceuticals US, Inc.$2K
- plus $9K from 31 others
What the payments were for
- Consulting fees$113,00085%
- Speaking & faculty fees$2,4502%
- Travel & lodging$4310%
- Food & beverage$16,09712%
- Education$2840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Preventice Services, LLC | 14 | $104,000 |
| Boston Scientific | 6 | $9,183 |
| Acist Medical Systems, Inc. | 7 | $3,237 |
| Abbott | 72 | $3,046 |
| Biotronik Inc. | 23 | $1,868 |
| Actelion Pharmaceuticals US, Inc. | 61 | $1,616 |
| Cardiovascular Systems Inc. | 13 | $1,347 |
| Shockwave Medical, Inc | 8 | $1,243 |
| Medtronic(2 entities) | 14 | $1,060 |
| Amgen | 31 | $859 |
| Bayer | 25 | $669 |
| Johnson & Johnson | 42 | $632 |
| AstraZeneca | 13 | $351 |
| Pfizer | 16 | $350 |
| Novartis | 20 | $350 |
| Inari Medical, Inc. | 3 | $331 |
| Regeneron Healthcare Solutions, Inc. | 15 | $293 |
| Esperion Therapeutics, Inc. | 13 | $285 |
| Abiomed | 2 | $264 |
| E.r. Squibb & Sons, L.L.C. | 12 | $251 |
| Portola Pharmaceuticals, LLC | 4 | $212 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $202 |
| Amarin Pharma, Inc. | 6 | $116 |
| Terumo Medical Corporation | 1 | $100 |
| Philips North America LLC | 2 | $63 |
| Baxter Healthcare | 2 | $49 |
| Veryan Medical Incorporated | 1 | $42 |
| Merck | 2 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $35 |
| Kestra Medical Technology Services, Inc. | 1 | $34 |
| Penumbra, Inc. | 1 | $29 |
| Cardiva Medical, Inc. | 1 | $21 |
| Heartflow, Inc. | 1 | $21 |
| Gilead | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Agepha Pharma FZ LLC | 1 | $14 |
| Infobionic, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BG Mini Plus$45,000
- Devices$2,450
- Diamondback Coronary$1,413
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,044
- Coronary Orbital Atherectomy System$677
- BioMonitor$675
- HD-IVUS$614
- Rivacor$277
- Solia$277
- Edora$277
- Acticor$277
- OPTIS$276
- UPTRAVI$274
- OPSUMIT$274
- Impella$264
- FLOWTRIEVER CATHETER, S$247
- CT THROMBECTOMY SYSTEM KIT$247
- XARELTO$244
- IN.PACT Admiral$236
- Emboshield NAV6 system$206
How this compares
$132,262 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 135 | $193,563 |
| Repatha SureclickEvolocumab | 215 | $168,982 |
| EliquisApixaban | 79 | $91,545 |
| EntrestoSacubitril/Valsartan | 73 | $87,609 |
| Praluent PenAlirocumab | 30 | $29,497 |
| FarxigaDapagliflozin Propanediol | 23 | $26,612 |
| Rosuvastatin Calcium | 408 | $7,508 |
| Metoprolol Succinate | 317 | $4,465 |
| Ezetimibe | 138 | $3,500 |
| Carvedilol | 171 | $1,493 |
| Flecainide Acetate | 39 | $1,478 |
| SotalolSotalol Hcl | 56 | $1,467 |
| Losartan Potassium | 165 | $1,414 |
| Nebivolol Hcl | 15 | $1,367 |
| Atorvastatin Calcium | 94 | $1,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $632 | $193,563135 claims |
| PfizerEliquis | $350 | $91,54579 claims |
| NovartisEntresto | $350 | $87,60973 claims |
| AstraZenecaFarxiga | $351 | $26,61223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Jose
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.